AbbVie’s Skyrizi (risankizumab-rzaa) Receives the US FDA’s Approval as the First Specific Interleukin-23 to Treat Moderately to Severely Active Crohn's Disease
Shots:
- The approval was based on the P-III (ADVANCE) & (MOTIVATE) as induction studies & (FORTIFY) as maintenance therapy evaluating Skyrizi vs PBO in patients with active CD
- In the 12wk. induction studies, patients achieved endoscopic response & clinical remission while clinical response & clinical remission as early as 4wk. In the 52wk. maintenance trial, patients achieved the co-1EPs of endoscopic response & clinical remission after 1yr. while few or no symptoms were reported along with a reduction of visible signs of intestinal inflammation in both trials
- The company offers a patient support program & co-pay card to provide patients access to Skyrizi & other therapy, and reduce out-of-pocket costs for eligible, commercially-insured patients to $5/mos.
Ref: AbbVie | Image: AbbVie
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
